Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses.

Pica N, Hai R, Krammer F, Wang TT, Maamary J, Eggink D, Tan GS, Krause JC, Moran T, Stein CR, Banach D, Wrammert J, Belshe RB, García-Sastre A, Palese P.

Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2573-8. doi: 10.1073/pnas.1200039109.

2.
3.

Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets.

Krammer F, Hai R, Yondola M, Tan GS, Leyva-Grado VH, Ryder AB, Miller MS, Rose JK, Palese P, García-Sastre A, Albrecht RA.

J Virol. 2014 Mar;88(6):3432-42. doi: 10.1128/JVI.03004-13.

4.

1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans.

Miller MS, Tsibane T, Krammer F, Hai R, Rahmat S, Basler CF, Palese P.

J Infect Dis. 2013 Jan 1;207(1):98-105. doi: 10.1093/infdis/jis652.

5.

Identification of amino acid substitutions supporting antigenic change of influenza A(H1N1)pdm09 viruses.

Koel BF, Mögling R, Chutinimitkul S, Fraaij PL, Burke DF, van der Vliet S, de Wit E, Bestebroer TM, Rimmelzwaan GF, Osterhaus AD, Smith DJ, Fouchier RA, de Graaf M.

J Virol. 2015 Apr;89(7):3763-75. doi: 10.1128/JVI.02962-14.

6.

B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza virus vaccination.

Sangster MY, Baer J, Santiago FW, Fitzgerald T, Ilyushina NA, Sundararajan A, Henn AD, Krammer F, Yang H, Luke CJ, Zand MS, Wright PF, Treanor JJ, Topham DJ, Subbarao K.

Clin Vaccine Immunol. 2013 Jun;20(6):867-76. doi: 10.1128/CVI.00735-12.

7.

Cross-reactive immunity against influenza viruses in children and adults following 2009 pandemic H1N1 infection.

Ahmed MS, Jacques LC, Mahallawi W, Ferrara F, Temperton N, Upile N, Vaughan C, Sharma R, Beer H, Hoschler K, McNamara PS, Zhang Q.

Antiviral Res. 2015 Feb;114:106-12. doi: 10.1016/j.antiviral.2014.12.008.

PMID:
25513756
8.

Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic А/California/07/2009(H1N1) influenza in healthy volunteers.

Desheva YA, Smolonogina TA, Donina SA, Rudenko LG.

BMC Res Notes. 2015 Apr 10;8:136. doi: 10.1186/s13104-015-1086-z.

9.

Development of neutralizing monoclonal antibodies against the pandemic H1N1 virus (2009) using plasmid DNA immunogen.

Cabral TM, Baig A, Berhane Y, Schmidt L, Hole K, Leith M, Kobasa D, Corbett CR.

J Virol Methods. 2014 Jan;195:54-62. doi: 10.1016/j.jviromet.2013.08.038.

PMID:
24060631
10.

A human monoclonal antibody derived from a vaccinated volunteer recognizes heterosubtypically a novel epitope on the hemagglutinin globular head of H1 and H9 influenza A viruses.

Boonsathorn N, Panthong S, Koksunan S, Chittaganpitch M, Phuygun S, Waicharoen S, Prachasupap A, Sasaki T, Kubota-Koketsu R, Yasugi M, Ono K, Arai Y, Kurosu T, Sawanpanyalert P, Ikuta K, Watanabe Y.

Biochem Biophys Res Commun. 2014 Sep 26;452(3):865-70. doi: 10.1016/j.bbrc.2014.09.008.

PMID:
25204499
11.
12.

Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans.

Nachbagauer R, Choi A, Izikson R, Cox MM, Palese P, Krammer F.

MBio. 2016 Jan 19;7(1):e01996-15. doi: 10.1128/mBio.01996-15.

13.

A novel pathogenic mechanism of highly pathogenic avian influenza H5N1 viruses involves hemagglutinin mediated resistance to serum innate inhibitors.

Panaampon J, Ngaosuwankul N, Suptawiwat O, Noisumdaeng P, Sangsiriwut K, Siridechadilok B, Lerdsamran H, Auewarakul P, Pooruk P, Puthavathana P.

PLoS One. 2012;7(5):e36318. doi: 10.1371/journal.pone.0036318.

14.

Addition of glycosylation to influenza A virus hemagglutinin modulates antibody-mediated recognition of H1N1 2009 pandemic viruses.

Job ER, Deng YM, Barfod KK, Tate MD, Caldwell N, Reddiex S, Maurer-Stroh S, Brooks AG, Reading PC.

J Immunol. 2013 Mar 1;190(5):2169-77. doi: 10.4049/jimmunol.1202433.

15.

[Monoclonal antibodies with high virus-neutralizing activity against pandemic influenza virus A/llV-Moscow/01/2009 (H1N1)swl].

Klimova RR, Masalova OV, Burtseva EI, Chichev EV, Lesnova EI, Oskerko TA, Mukasheva EA, Rudneva IA, Lvov DK, Kushch AA.

Vopr Virusol. 2011 May-Jun;56(3):15-20. Russian.

PMID:
21786621
16.

Induction of broadly neutralizing H1N1 influenza antibodies by vaccination.

Wei CJ, Boyington JC, McTamney PM, Kong WP, Pearce MB, Xu L, Andersen H, Rao S, Tumpey TM, Yang ZY, Nabel GJ.

Science. 2010 Aug 27;329(5995):1060-4. doi: 10.1126/science.1192517.

17.

Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones.

He W, Mullarkey CE, Duty JA, Moran TM, Palese P, Miller MS.

J Virol. 2015 Apr;89(7):3610-8. doi: 10.1128/JVI.03099-14.

18.

Hemagglutinin Stalk-Reactive Antibodies Are Boosted following Sequential Infection with Seasonal and Pandemic H1N1 Influenza Virus in Mice.

Krammer F, Pica N, Hai R, Tan GS, Palese P.

J Virol. 2012 Oct;86(19):10302-7. doi: 10.1128/JVI.01336-12.

19.

Neutralizing and protective epitopes of the 2009 pandemic influenza H1N1 hemagglutinin.

Schmeisser F, Friedman R, Besho J, Lugovtsev V, Soto J, Wang W, Weiss C, Williams O, Xie H, Ye Z, Weir JP.

Influenza Other Respir Viruses. 2013 May;7(3):480-90. doi: 10.1111/irv.12029.

20.

Development and characterization of neutralizing monoclonal antibodies against the pandemic H1N1 virus (2009).

Cabral TM, Berhane Y, Schmidt L, Tracz DM, Hole K, Leith M, Corbett CR.

J Virol Methods. 2012 Jul;183(1):25-33. doi: 10.1016/j.jviromet.2012.03.016.

PMID:
22575685
Items per page

Supplemental Content

Support Center